Genentech-partnered Novome lands $43.5M to push gastrointestinal drug through mid-stage study
A biotech with connections to Roche’s Genentech has now landed its newest cash infusion.
Microbiome outfit Novome Biotechnologies said Tuesday that it has now secured $43.5 million in new financing via a Series B round. The funds, according to the company, will be used to advance its lead candidate through an ongoing Phase IIa — and advance other candidates for a potential indication in inflammatory bowel disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.